Key result
Prediabetes shows no association with 30-day MACE versus normal glucose metabolism in STEMI.
Why the study?
Does prediabetes or newly diagnosed diabetes predict short-term mortality and MACE in nondiabetic patients with STEMI?
Cohort (n=4,787)
Does prediabetes or newly diagnosed diabetes predict short-term mortality and MACE in nondiabetic patients with STEMI?
Hazard Ratio: 1.003 (95% CI 0.865–1.165)
In nondiabetic patients with STEMI, admission glucose level, rather than HbA1c-defined prediabetes or newly diagnosed diabetes, is an independent predictor of short-term MACE.
HbA1c-defined prediabetes should not guide 30-day MACE risk assessment in STEMI; leaves open admission glucose as potential marker in nondiabetics.
OBJECTIVES: A prediabetic state is defined as the time period before the development of symptomatic diabetes. Limited evidence is available for evaluating the correlation between prediabetes and short-term outcomes in nondiabetic patients with ST-elevation of myocardial infarction (STEMI). METHODS: 4,787 nondiabetic patients with a diagnosis of STEMI based on typical onset of chest pain within 12 h were enrolled. Patients were followed up for 7 and 30 days after hospital admission. According to the 2013 Standards of Medical Care in Diabetes, the study population was stratified into three groups: normal, prediabetic and newly diagnosed diabetic patients. The primary outcomes of our study were all-cause mortality and major adverse cardiac events (MACE) on days 7 day and 30. RESULTS: The proportions of patients with prediabetes and newly diagnosed diabetes were 31.1 and 19.2%, respectively. Rates of 7- and 30-day mortality and MACE were similar among the different HbA1c groups. Multivariable Cox regression analysis showed that compared with normal glucose metabolism, prediabetes (hazard ratio, HR, 1.003; 95% CI, 0.865-1.165) and newly diagnosed diabetes (HR, 0.887; 95% CI, 0.739-1.064) were not correlated with 30-day MACE. However, admission glucose was an independent predictor of short-term MACE (HR, 1.031; 95% CI, 1.017-1.046). CONCLUSIONS: In nondiabetic patients after STEMI, the incidence of latent diabetes mellitus was increased. Newly diagnosed diabetes and prediabetes were not correlated with short-term outcome in nondiabetic patients with STEMI, yet admission glucose level was an independent predictor of short-term MACE. To reduce the incidence of short-term MACE after STEMI, more attention should be paid to the control of increased glucose levels and intrinsic stress states.
No takes yet. Share an insight, caveat, or question.
Li et al. (2013) conducted a cohort in ST-elevation myocardial infarction (STEMI) (n=4,787). Prediabetes vs. Normal glucose metabolism was evaluated on All-cause mortality and major adverse cardiac events (MACE) on days 7 and 30 (HR 1.003, 95% CI 0.865-1.165). In nondiabetic patients with STEMI, prediabetes was not correlated with 30-day major adverse cardiac events compared with normal glucose metabolism (HR 1.003; 95% CI 0.865-1.165).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: